research use only
Cat.No.S4008
| Related Targets | Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR |
|---|---|
| Other Histamine Receptor Inhibitors | GSK2879552 Dihydrochloride JNJ-7777120 Ebastine Ciproxifan Maleate Mianserin HCl Astemizole Lafutidine Mizolastine Rupatadine Fumarate Betahistine 2HCl |
| Molecular Weight | 266.3 | Formula | C10H7N6O.K |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 100299-08-9 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | BMY26517 | Smiles | CC1=CC=CN2C1=NC=C(C2=O)C3=NN=N[N-]3.[K+] | ||
|
In vitro |
Water : 53 mg/mL
DMSO
: Insoluble
Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Targets/IC50/Ki |
Histamine H1 receptor
|
|---|---|
| In vitro |
Pemirolast potassium (BMY 26517) is a new oral, nonbronchodilator antiallergy medication that is being evaluated for the therapy of asthma. This compound inhibits chemical mediator release from tissue mast cells and is also shown to inhibit the release of peptides including substance P, neurokinin (NK) A, and calcitonin gene-related peptide (CGRP) from sensory nerves. It is used for the treatment of allergic conjunctivitis and prophylaxis for pulmonary hypersensitivity reactions to drugs such as paclitaxel.
|
| In vivo |
Pemirolast potassium (BMY 26517) reduces kaolin intake by inhibition of substance P release in rats. This compound potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats.
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.